For other people named David Taylor, see David Taylor.
At the Maudsley Guidelines Conference in 20251st Edition 2020
David Taylor FFRPS FRPharmS (born 1963) is a British professor. He is the head of the Pharmaceutical Sciences Clinical Academic Group within King's Health Partners. Taylor has been lead author and editor of the Maudsley Prescribing Guidelines in Psychiatry since 1994. In 2014, Taylor was named as one of the top 100 clinical leaders in the UK National Health Service.[1]
Taylor was born in Leicester in 1963 and attended Loughborough Grammar School (1975-1982). He is the second of four brothers. His younger brother is the presenter and historian, Stephen Taylor.[2] His father, James Taylor CChemMRSC, contributed to the development of sodium cromoglycate.[3]
Published April 2025
Taylor was guitarist in New Wave group The Thought Police, who supported Theatre of Hate on their 1981 UK tour.
A keen rugby player, Taylor played three seasons for Loughborough Grammar School first team and was later captain of Old Pauline FC 1st XV, for whom he made over 300 appearances, many alongside fellow Old Loughburian Patrick MacLarnon.
In 2023, Taylor completed the London Marathon in just over four hours.
Taylor's first experience in psychiatry was in 1986 – a brief placement at the Towers Hospital in Leicester. He then worked in general medicine at hospitals in London and Sydney until joining the Maudsley hospital in 1993. In 1997 Taylor founded the national centre for information on drugs in psychiatry, part of the UKMi network. He has been head of pharmacy since 1995 and Director of Pharmacy and Pathology at the South London and Maudsley NHS Foundation Trust since 2000.
Taylor was chairman of the UK Psychiatric Pharmacy Group (1997-1999) and the foundation president of the College of Mental Health Pharmacists, a role recognised by the award of a lifetime fellowship (FCMHP). He was a member of the government-appointed panel which brought in laws in drug driving[6] and between 2020 and 2024 was a member of the Advisory Council on the Misuse of Drugs.[7]
Taylor has been a member of several NICE panels responsible for drawing up treatment guidelines in mental health, including the 2022 guideline on depression in adults.[8]
Since 2011 he has been editor-in-chief of the journal Therapeutic Advances in Psychopharmacology[9] which was launched in the same year. The journal has an official Impact Factor of 4.0[10] and is ranked 54th out of 288 psychiatry journals.
Taylor is widely recognised as an expert witness on the effect of drugs on behaviour and has given testimony on over two hundred civil and criminal cases.
Research
Taylor has authored around 425 papers (H index78) in journals such as the Lancet, BMJ, British Journal of Psychiatry and Journal of Clinical Psychiatry, on subjects ranging from the value of long-acting antipsychotic injections,[11][12] the efficacy of psilocybin as an antidepressant and the efficacy and safety of agomelatine. Taylor’s research has helped further understanding of the use of clozapine.[13][14][15][16][17][18] In 2022 he suggested a refined phenotype for genetic studies into clozapine-related agranulocytosis.[19] His work[20][21] directly contributed to the change in clozapine monitoring requirements announced by the European medicines Agency. He has also developed a genetic test predicting response to clozapine and the risk of agranulocytosis. This test is marketed in the UK by Myogenes. Most recently Taylor has tackled the controversial subjects of discontinuation of antidepressants[22][23] and antipsychotics.[24][25] He is co-founder of 428 Pharma a company developing the world's first antidepressant long-acting injection which is designed for use both as longterm treatment and, at different dosage levels, as a means of successfully withdrawing from antidepressant treatment. Taylor has pioneered the use of point-of-care capillary testing for clozapine[26][27]
Maudsley Prescribing Guidelines
Taylor was the originator of the idea of an evidenced-based mental health prescribing guideline along with the late professor Robert Kerwin and has made a major and unique contribution by writing the Maudsley Prescribing Guidelines[28] for over 30 years. Taylor is the de facto editor of this publication and is the only author to be credited on all 15 editions. The Maudsley Prescribing Guidelines[29][30][31] have sold over 300,000 copies in thirteen languages. The 15th edition was published in April 2025. He has also co-written four other books in the Maudsley Prescribing Guidelines series, including The Maudsley Deprescribing Guidelines, first published in January 2024.
Atypical antipsychotics and weightgain—a systematic review, DM Taylor, R McAskill, Acta Psychiatrica Scandinavica 101 (6), 416–432, 2000
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014 Mar 19;348:g1888. David Taylor, Anna Sparshatt, Seema Varma, Olubanke Olofinjana
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study, RL Carhart-Harris, M Bolstridge, J Rucker, CMJ Day, D Erritzoe, M Kaelen, The Lancet Psychiatry 3 (7), 619-627 2016.
Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019; 6: 538–546. Horowitz MA Taylor D
↑ "TV & Media". Stephen Taylor, WW2 Relic Hunter. 18 January 2018. Retrieved 31 January 2023.
↑ Bell, J. H.; Stevenson, N. A.; Taylor, J. E. (1973). "A moisture transfer effect in hard gelatin capsules of sodium cromoglycate". The Journal of Pharmacy and Pharmacology. 25: Suppl:96P–103. PMID4150598.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
